8-K: BriaPro Therapeutics Reports Q3 2024 Financial Results and Provides Business Update

BriaPro Therapeutics, a subsidiary of BriaCell, released its unaudited financial statements for the three months ended October 31, 2024, highlighting ongoing research and development activities and a net loss.

Summary

• BriaPro Therapeutics Corp., a two-thirds owned subsidiary of BriaCell Therapeutics Corp., has released its unaudited condensed interim consolidated financial statements for the three-month period ended October 31, 2024.
• The company reported a net loss of $82,123 for the quarter, compared to a loss of $128,026 for the same period in 2023.
• Research and development expenses were $48,500, a decrease from $64,460 in the prior year's quarter.
• General and administrative expenses also decreased to $22,503 from $67,303 in the same period of 2023.
• The change in fair value of the warrant liability resulted in a loss of $11,120 for the quarter.
• BriaPro's cash and cash equivalents remained at $1, with a negative working capital of $522,834.
• The company is currently in the pre-clinical research stage and has not commenced commercial operations.
• BriaPro is dependent on BriaCell for financing and is exploring additional sources of capital.
• The company is developing Bria-TILsRx and PKC inhibitors for cancer treatment, utilizing AI for drug discovery.
• Human clinical studies for Bria-TILsRx are expected to begin in the first half of 2025, and for PKC inhibitors in the second half of 2025.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in research and development, the company's financial situation is concerning, with a net loss, negative working capital, and dependence on external funding. The early stage of development and reliance on third parties also contribute to a cautious sentiment.

Positives

• BriaPro's net loss decreased compared to the same period last year, from $128,026 to $82,123.
• Research and development expenses have decreased, indicating a potential shift in spending or efficiency.
• General and administrative expenses have significantly decreased, suggesting cost-cutting measures or a reduction in external services.
• The company is actively developing novel immunotherapies and small molecule inhibitors for cancer treatment.
• BriaPro is leveraging AI for drug discovery, which could accelerate the development process.
• The company has filed a provisional patent application for its newly designed antibodies.
• BriaPro has a clear timeline for initiating human clinical studies for both Bria-TILsRx and PKC inhibitors.

Negatives

• BriaPro reported a net loss of $82,123 for the quarter.
• The company has a negative working capital of $522,834.
• BriaPro is dependent on BriaCell for financing and has not yet achieved commercial operations.
• The company's cash and cash equivalents remain at a very low level of $1.
• The change in fair value of the warrant liability resulted in a loss of $11,120 for the quarter.
• The company is in the pre-clinical research stage, indicating a long road to potential revenue generation.

Risks

• BriaPro's ability to continue as a going concern is dependent on securing additional financing.
• The company is in the early stages of development and faces significant risks associated with clinical trials and regulatory approvals.
• BriaPro is reliant on third-party suppliers and contract research organizations, which could lead to delays or supply issues.
• The market for cancer therapeutics is highly competitive, and BriaPro faces competition from companies with greater resources.
• The company's intellectual property is subject to risks of infringement and may not provide adequate protection.
• BriaPro is dependent on key personnel, and the loss of any of these individuals could adversely affect the business.
• The company has a limited operating history and no operating revenues.
• There is no assurance that BriaPro shares will ever be listed on a stock exchange.
• The company is subject to various regulatory risks and may face challenges in obtaining necessary approvals.
• BriaPro is subject to product liability risks and may face lawsuits if its products cause harm.

Future Outlook

BriaPro expects to screen several multi-specific binding reagents and select at least one candidate for IND enabling studies. Human clinical studies are expected to begin in the first half of 2025 for Bria-TILsRx and in the second half of 2025 for PKC inhibitors. The company also plans to optimize the structure of its proprietary protein kinase C delta inhibitors.

Management Comments

• Management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made.
• Management understands that the Company is exposed to financial risk arising from fluctuations in foreign exchange rates.
• Management believes that the credit risk concentration with respect to financial instruments is remote.

Industry Context

This announcement comes as the biotechnology industry continues to focus on innovative cancer therapies, particularly immunotherapies and targeted small molecule inhibitors. The use of AI in drug discovery is a growing trend, and BriaPro's approach aligns with this direction. The company's focus on multi-specific binding reagents and PKC inhibitors positions it within a competitive but potentially lucrative market.

Comparison to Industry Standards

• BriaPro's financial results are typical for an early-stage pre-clinical biotechnology company, with significant losses and minimal revenue.
• Compared to companies like Adaptimmune Therapeutics and Kite Pharma, which are also developing cell-based immunotherapies, BriaPro is at a much earlier stage of development.
• Companies like Relay Therapeutics and Blueprint Medicines, which focus on small molecule inhibitors, are further along in clinical development than BriaPro.
• BriaPro's reliance on AI for drug discovery is similar to companies like Exscientia and Insilico Medicine, but BriaPro is still in the early stages of applying this technology.
• The negative working capital and dependence on BriaCell for funding are common challenges for early-stage biotech companies, but highlight the need for BriaPro to secure additional capital.

Related Party Transactions

• As of October 31, 2024, the total balance owing to BriaCell group companies is $503,709.
• For the three month period ending October 31, 2024 the fixed monthly services expense totaled $60,000 and direct expenses incurred by Briacell on behalf of BriaPro totaled $19,055.
• During the three-month period ended October 31, 2024, the Company incurred Services and direct expense paid for by Briacell in the amount of $79,055.

Stakeholder Impact

• Shareholders face the risk of dilution from future capital raises.
• Employees are subject to the uncertainty of the company's financial stability.
• Customers (potential patients) may benefit from the development of new cancer therapies, but these are still in early stages.
• Suppliers and contract research organizations are dependent on BriaPro's ability to secure funding.
• Creditors face the risk of non-payment if the company fails to secure additional financing.

Next Steps

• BriaPro expects to screen several multi-specific binding reagents for activity in vitro and in mouse models of cancer.
• The company expects to select at least one candidate to advance into IND enabling studies.
• Human clinical studies are expected to be initiated in the first half of 2025 for Bria-TILsRx.
• Human clinical studies are expected to be initiated in the second half of 2025 for PKC inhibitors.
• BriaPro will continue to optimize the structure of its proprietary protein kinase C delta inhibitors.

Key Dates

Keywords

BriaPro Therapeutics, BriaCell Therapeutics, Immunotherapy, Cancer, PKC Inhibitors, Bria-TILsRx, AI Drug Discovery, Clinical Trials, Biotechnology, Financial Results